NUZYRA for NTM Lung Disease from MAC Earns Fast Track Designation
oracast / Pixabay

NUZYRA for NTM Lung Disease from MAC Earns Fast Track Designation

  In the United States, during the drug development and approval process, drug developers are able to request Fast Track designation. This process is designed to facilitate and expedite the…

Continue Reading NUZYRA for NTM Lung Disease from MAC Earns Fast Track Designation
Vilobelimab for Pyoderma Gangrenosum Earns Orphan Drug Designation
Source: https://pixabay.com/en/thumb-up-like-sign-hand-ok-good-441938/

Vilobelimab for Pyoderma Gangrenosum Earns Orphan Drug Designation

  At the end of June 2022, biopharmaceutical company InflaRx N.V. (“InflaRx”) shared via press release that its product vilobelimab recently earned Orphan Drug designation in both the United States…

Continue Reading Vilobelimab for Pyoderma Gangrenosum Earns Orphan Drug Designation
Study Shows Keratoconus Patients Have Permanent Corneal Structure Changes If Unable to Get Timely Corneal Crosslinking
source: pixabay.com

Study Shows Keratoconus Patients Have Permanent Corneal Structure Changes If Unable to Get Timely Corneal Crosslinking

According to a recent article, a study has shown that keratoconus patients who do not get their timely corneal crosslinking will have permanent changes in their corneal structure.   Keratoconus…

Continue Reading Study Shows Keratoconus Patients Have Permanent Corneal Structure Changes If Unable to Get Timely Corneal Crosslinking
Charcot-Marie-Tooth Disease: Theophylline Boosts Myelin Production in CMT1A Mice
source: unsplash.com

Charcot-Marie-Tooth Disease: Theophylline Boosts Myelin Production in CMT1A Mice

According to a story from Charcot-Marie-Tooth News, a recent study using a mouse model of Charcot-Marie-Tooth disease type 1A produced some interesting results. The researchers found that administration of theophylline…

Continue Reading Charcot-Marie-Tooth Disease: Theophylline Boosts Myelin Production in CMT1A Mice
ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint
source: pixabay.com

ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint

  Findings from the MITO23 Trial investigating the outcome of the chemotherapy drug trabectedin against physician’s choice to treat BRCA-mutated patients with ovarian cancer were presented at ASCO’s 2022 Annual…

Continue Reading ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint
ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency
source: unsplash.com

ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency

  The ENDO 2022 Annual Congress took place from June 11-14, 2022. During the Congress, stakeholders met to discuss care, treatments, and research within endocrinology. In a news release from…

Continue Reading ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency
New Program Evaluates the Adaptability of Precision Medicine to Identify Over 400 Genetic Disorders and Potential Treatments
source: pixabay.com

New Program Evaluates the Adaptability of Precision Medicine to Identify Over 400 Genetic Disorders and Potential Treatments

  The novel program called BeginNGS™ was described in a recent article which has a goal of testing for five hundred disorders and several thousand infants. Rady Children's Institute for…

Continue Reading New Program Evaluates the Adaptability of Precision Medicine to Identify Over 400 Genetic Disorders and Potential Treatments
This Nonprofit’s Clinical Trial Committee Aims to Help Rett Syndrome Drug Development
source: pixabay.com

This Nonprofit’s Clinical Trial Committee Aims to Help Rett Syndrome Drug Development

According to a story from news-medical.net, the International Rett Syndrome Foundation (IRSF) has announced the launch of its Clinical Trial Committee. The committee was implemented with the goal of helping…

Continue Reading This Nonprofit’s Clinical Trial Committee Aims to Help Rett Syndrome Drug Development